Anti-anthrax monoclonal antibodies - IQ Therapeutics
Alternative Names: Anthraxumab; anti-LF; anti-PA; IQ-DAA; IQ-NLF; IQ-NPA; IQNLF-1Latest Information Update: 02 Oct 2021
At a glance
- Originator IQ Therapeutics
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Anthrax toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Anthrax(In volunteers) in Netherlands (Injection)
- 26 Apr 2011 IQ Therapeutics completes enrolment in its phase I trial for Anthrax (in volunteers) in the Netherlands
- 24 Feb 2011 Phase-I clinical trials in Anthrax (in volunteers) in Netherlands (Injection)